Cytokinetics is a biotechnology business based in the US. Cytokinetics shares (CYTK) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $36.67 – a decrease of 11.19% over the previous week. Cytokinetics employs 498 staff and has a trailing 12-month revenue of around $18.5 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $36.67 |
|---|---|
| 52-week range | $32.74 - $68.44 |
| 50-day moving average | $42.03 |
| 200-day moving average | $49.67 |
| Wall St. target price | $76.71 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-5.26 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $37.35 from 2025-05-02
| 1 week (2025-04-29) | -9.54% |
|---|---|
| 1 month (2025-04-07) | 3.78% |
| 3 months (2025-02-07) | -12.65% |
| 6 months (2024-11-07) | -33.11% |
| 1 year (2024-05-07) | -42.78% |
|---|---|
| 2 years (2023-05-05) | -5.30% |
| 3 years (2022-05-06) | 38.06 |
| 5 years (2020-05-06) | 124.59% |
| Revenue TTM | $18.5 million |
|---|---|
| Gross profit TTM | $-320,934,016 |
| Return on assets TTM | -30.11% |
| Return on equity TTM | -572.15% |
| Profit margin | 0% |
| Book value | $-1.15 |
| Market Capitalization | $4.5 billion |
TTM: trailing 12 months
We're not expecting Cytokinetics to pay a dividend over the next 12 months.
Cytokinetics's shares were split on a 1:6 basis on 24 June 2013 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytokinetics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cytokinetics shares which in turn could have impacted Cytokinetics's share price.
Over the last 12 months, Cytokinetics's shares have ranged in value from as little as $32.74 up to $68.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytokinetics's is 0.939. This would suggest that Cytokinetics's shares are less volatile than average (for this exchange).
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. .
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.